Italia - italiano - myHealthbox

basilea medical ltd. - ceftezolo - polvere per concentrato per soluzione per infusione - ogni flaconcino contiene 500 mg di ceftobiprolo. dopo la ricostituzione, ogni ml di concentrato contiene 50 mg di ceftobiprolo - altre cefalosporine - trattamento delle infezioni: polmonite acquisita in ospedale (hap) esclusa la polmonite associata a ventilazione meccanica (ventilator-associated pneumonia, vap), polmonite acquisita in comunità (cap)

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

rottapharm s.p.a. - acido tranexamico - acido tranexamico

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

malesci istituto farmacobiologico s.p.a. - acido tranexamico - acido tranexamico

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

aspen pharma trading limited - clorambucile - clorambucile

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sanofi s.r.l. - danazolo - danazolo

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

bioindustria laboratorio italiano medicinali s.p.a. - acido tranexamico - acido tranexamico

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

correvio - ceftobiprolo medocaril - ceftobiprolo medocaril

Unione Europea - italiano - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Unione Europea - italiano - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - antibatterici per uso sistemico, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. dovrebbero essere prese in considerazione le linee guida ufficiali sull'uso appropriato degli agenti antibatterici..

Unione Europea - italiano - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - ceftolozane solfato, tazobactam sodico - infezioni batteriche - antibatterici per uso sistemico, - zerbaxa is indicated for the treatment of the following infections in adults:complicated intra abdominal infections;acute pyelonephritis;complicated urinary tract infections;hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap). dovrebbero essere prese in considerazione le linee guida ufficiali sull'uso appropriato degli agenti antibatterici..